Verve Therapeutics Financials
| VERV Stock | USD 5.29 0.44 9.07% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.47 | 17.2391 |
|
|
The essential information of the day-to-day investment outlook for Verve Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Verve Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Verve Therapeutics.
Net Income |
|
Verve | Select Account or Indicator |
Understanding current and past Verve Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Verve Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Verve Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Verve Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Verve Therapeutics. Check Verve Therapeutics' Beneish M Score to see the likelihood of Verve Therapeutics' management manipulating its earnings.
Verve Therapeutics Stock Summary
Verve Therapeutics competes with Adaptive Biotechnologies, Beam Therapeutics, Caribou Biosciences, Sana Biotechnology, and Intellia Therapeutics. Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Verve Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 113 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US92539P1012 |
| CUSIP | 92539P101 |
| Location | Massachusetts; U.S.A |
| Business Address | 201 Brookline Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.vervetx.com |
| Phone | 617 603 0070 |
| Currency | USD - US Dollar |
Verve Therapeutics Key Financial Ratios
| Return On Equity | -0.41 | ||||
| Operating Margin | (8.29) % | ||||
| Price To Sales | 16.83 X | ||||
| Revenue | 11.76 M | ||||
| Gross Profit | (128.15 M) |
Verve Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Verve Therapeutics's current stock value. Our valuation model uses many indicators to compare Verve Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Verve Therapeutics competition to find correlations between indicators driving Verve Therapeutics's intrinsic value. More Info.Verve Therapeutics is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Verve Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Verve Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Verve Therapeutics Systematic Risk
Verve Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Verve Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Verve Therapeutics correlated with the market. If Beta is less than 0 Verve Therapeutics generally moves in the opposite direction as compared to the market. If Verve Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Verve Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Verve Therapeutics is generally in the same direction as the market. If Beta > 1 Verve Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Verve Therapeutics Thematic Clasifications
Verve Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Today, most investors in Verve Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Verve Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Verve Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Verve Therapeutics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Verve Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Verve Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Verve Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Verve Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Verve Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.72 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 22.1 | |||
| Value At Risk | (9.25) | |||
| Potential Upside | 7.71 |
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.